What Rheosorbilact Treats: Main Uses and Benefits

Rheosorbilact is applied across domains where additional symptomatic support is needed in acute medical settings. It is relevant for easing symptoms related to three primary areas: impaired blood flow (circulatory support), systemic imbalance (like acidosis), and widespread intoxication during severe illness.

It is relevant in conditions characterized by periods of heightened symptoms, which may include systemic disturbances related to severe inflammation, trauma, or infection.

This medication assists with managing symptom clusters that may become intense or disruptive.

“It provides support that contributes to easing the overall symptom load during periods of heightened symptoms.”

This assistance with symptom management may help patients cope more steadily with system-wide manifestations of severe illness and assists with maintaining functional stability.

---

Quick Fact: Relief for Acute Systemic Strain

Regulatory References

1. ClinicalTrials.gov website

Who Can and Cannot Use Rheosorbilact?

The eligibility for using Rheosorbilact is strictly defined by regulatory documents based on the patient's underlying metabolic, volume, and electrolyte status. The solution is primarily intended for the adult population, aged 18 to 60 years, requiring fluid and chemical balance correction.

Absolute Contraindications

Rheosorbilact must not be used in patients with:

• Fluid or Volume Overload: Including hypervolemia or extracellular hyperhydration.
• Severe Metabolic Imbalance: Specifically metabolic alkalosis or severe metabolic acidosis.
• Electrolyte Excess: Including hyperkalemia or hypercalcemia.
• Cardiovascular Risks: Such as decompensated cardiovascular failure or Grade III arterial hypertension.
• Other Prohibitions: Including intracerebral hemorrhage, any thromboembolism, or hypersensitivity to solution components.

Restricted and Special Populations

Use is not established in pediatric patients (under 18 years). Extreme caution is required in older adults (over 60 years) due to increased frequency of reduced organ function. The medicine is also listed as an exclusion criterion and is contraindicated during pregnancy and breastfeeding. Eligibility is further restricted in patients with severe renal dysfunction or severe hepatic insufficiency due to impaired clearance of electrolytes and lactate.

Interactions with other medicines and products

Official regulatory information for poly-electrolyte solutions containing Sodium Lactate and Calcium, which are core components of Rheosorbilact, identifies several formal interaction constraints and prohibitions.

Contraindicated Combinations

The medicine is officially contraindicated for co-administration with Ceftriaxone in neonates (patients le 28 days old) due to the documented risk of ceftriaxone-calcium salt precipitation. Co-administration with Digitalis cardiac glycosides (e.g., Digoxin) is also formally contraindicated due to the risk of severe cardiac arrhythmias linked to the solution's calcium content.

Pharmacodynamic and Exposure Interactions

The solution interacts with several product categories based on its electrolyte components. Co-administration with Potassium-sparing diuretics, ACE Inhibitors, and ARBs is associated with an increased, documented risk of hyperkalaemia. The combination with Thiazide diuretics or Vitamin D analogs carries a documented risk of hypercalcaemia.

Additionally, the solution's metabolic effect can alter the clearance of other drugs. The administration may result in increased renal clearance (reduced exposure) of acidic medicines such as Salicylates, Barbiturates, and Lithium, due to urinary alkalinisation.

Administration and Population Constraints

Specific timing-based rules apply to Ceftriaxone in patients older than 28 days: it must not be administered simultaneously through the same infusion line, requiring a thorough flush with compatible fluid between administrations. Regulatory documents also note that Severe Hepatic Impairment is a factor that may affect the metabolism of the solution's lactate component.

Osmotic Action and Volume Expansion

The core mechanism is driven by Sorbitol, which generates a high osmotic gradient in the bloodstream. This gradient forces a rapid shift of water from the interstitial fluid spaces into the circulating plasma, resulting in the expansion of intravascular volume and an improvement in blood rheology (flow dynamics). This action enhances tissue perfusion and aids in initiating systemic fluid clearance.

---

Metabolic Conversion for Acid-Base Balance

The solution acts as an indirect alkalizing agent via the metabolic precursor Sodium Lactate. The Lactate anion is processed primarily by liver enzyme systems to generate essential bicarbonate ( HCO3^-) buffer. The subsequent increase in HCO3^- effectively buffers (consumes) excess hydrogen ions (H^+), supporting the chemical adjustment of metabolic acidosis and maintaining the internal pH range required for optimal cellular enzyme function.

---

Electrolyte Homeostasis and Cellular Stabilization

The solution provides a balanced profile of essential mineral salts ( Na^+, K^+, Ca^2+, Mg^2+) that directly regulate electrolyte homeostasis. These ions modulate ion channels and transporters, maintaining the resting membrane potential of excitable cells. The primary physiological consequence is the stabilization of neuromuscular and cardiac function, contributing to the maintenance of electrical signaling and muscle contraction, even during rapid fluid and chemical shifts.

Administration Route and Dosing

Rheosorbilact is a sterile solution strictly administered through intravenous (IV) infusion under the supervision of medical professionals. The volume to be administered is determined based on the patient's body weight, with the calculation typically utilizing a range of 10 to 15 ml per kilogram of body weight over a 24-hour period. For standard adult use, the total administered volume is generally restricted to a maximum of 1,000 ml per day. This volume is given daily, often requiring the total amount to be divided into multiple, scheduled infusions.

---

Procedural Requirements and Duration

The administration procedure itself is highly specific. The solution must be infused slowly and consistently at a rate specified to be between 40 and 60 drops per minute. Dosing may require adjustment for specific populations; for example, protocols for certain patients may impose maximum volumes of 200 ml or 400 ml based on body weight and renal status. This therapy is intended as a short-term course with a typical duration of 3 days.

Research Evidence / Overview of Studies for Rheosorbilact

---

Evidence for Use in Severe Systemic Strain and Inflammation

This section describes the types of research available, including Randomized Controlled Trials (RCTs) and multicenter studies, that explored Rheosorbilact in critically ill patients with conditions like severe pneumonia and sepsis. It outlines how researchers monitored parameters (e.g., acid-base balance, intoxication markers) in the studies.

Research exploring this solution was studied for use in patients with severe conditions, such as severe pneumonia, sepsis, and purulent peritonitis. The main focus of these studies was to monitor changes in disease severity scales and biomarkers reflecting the body's level of intoxication. Some trials described patterns where measurements of circulatory blood volume and hemodynamic stability (blood pressure and heart rate) were monitored during the administration of the solution. These findings describe patterns observed in the short study period, but research does not determine whether an individual will respond similarly.

Fewer data are available for certain specific subgroups, such as the elderly (over 60), who were not the primary populations studied.

---

Evidence for Use in Acute Fluid Instability and Trauma

This section describes the types of research available, including clinical trials and protocols, that explored the solution in contexts of acute volume deficit, such as in patients with severe burns or traumatic injury. It outlines how researchers monitored parameters (e.g., circulatory stability, volume restoration) in the studies.

Studies exploring the use of this solution in patients with acute trauma were evaluated as a fluid management strategy during the crucial early hours of treatment. The outcomes measured included parameters reflecting physiological strain, such as the restoration of circulating blood volume and the stabilization of hemodynamic parameters. The findings describe patterns observed in the studies and primarily evaluated the immediate treatment phase. A key limitation here is the nature of the research: the focus is on the immediate acute phase, and the follow-up durations were limited.

---

What Remains Uncertain and Gaps in the Research

There are several areas where certainty remains low or where additional research is needed. As noted, long-term effects are not fully established, as the duration of follow-up in key trials was short. This limits understanding of patterns related to long-term functional recovery. Furthermore, sample sizes were modest in some of the more specialized sub-studies, which means that results apply only to the populations studied and cannot necessarily be generalized widely.

Key Studies & References

1. Study Details | NCT03824457 | Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia | ClinicalTrials.gov
2. The first data on international multicenter clinical study RheoSTAT-CP0691 on the efficacy and safety of Rheosorbilact® infusion in therapy of purulent peritonitis

Common questions about Rheosorbilact (FAQ)

Q: Is Rheosorbilact a prescription medication or an over-the-counter drug?

Rheosorbilact is not an over-the-counter medicine. It is exclusively supplied as a sterile solution intended for intravenous (IV) infusion and is designed for administration strictly under the direct supervision of qualified medical professionals in a clinical setting.

Q: How quickly can one expect to see an effect after using Rheosorbilact?

The key action of correcting metabolic acidosis (a chemical imbalance) is related to the Sodium Lactate component, which the body must first process. Studies and official information indicate this correcting effect typically manifests approximately 20 to 30 minutes after administration has been completed.

Q: What are the most common minor side effects associated with Rheosorbilact?

Official documents note that common concerns include minor changes in fluid and electrolyte balance and reactions where the solution is infused (infusion site reactions). Reports from studies on similar solutions also mention a temporary feeling of warmth, slight headache, or a temporary decrease in heart rate. These reactions are thought to be related to the fluid shifts that the solution is designed to facilitate.

Q: Does Rheosorbilact interact with common pain relievers like ibuprofen?

The regulatory documents indicate that the solution's metabolic action can cause a slight increase in the renal clearance (removal) of certain acidic medicines. Because some common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen, fall into this category, co-administration may require careful monitoring.

Q: Does Rheosorbilact cause any changes in weight?

Weight changes are not listed as a common or minor side effect. However, the official safety profile notes that a serious adverse reaction is Severe Hypervolemia (fluid overload). This condition results in significant fluid retention, which can cause temporary weight gain and edema.

Q: Is Rheosorbilact known to interfere with routine blood tests?

The solution's complex composition and rapid metabolic effects require careful monitoring of the patient. The hyperosmolality (high concentration) and the breakdown of Sorbitol may specifically influence the results of certain clinical tests, such as blood sugar readings.

Q: Why do some people report feeling tired after Rheosorbilact use?

Official adverse reaction listings for similar poly-electrolyte solutions include reports of unusual tiredness or weakness (fatigue). These types of effects may occur as the body adjusts to the fluid and electrolyte shifts.

Q: How long does Rheosorbilact stay in the body after the treatment is finished?

The solution's active components are rapidly metabolized or cleared. The organic molecules Sorbitol and Lactate are converted by the liver into energy sources and chemical buffers. Due to the solution's hyperosmolarity and acute purpose, its main effects on microcirculation and toxin mobilization are measured in the short term, often within 4 to 6 hours.

Q: Is it normal to feel a warming sensation when Rheosorbilact is administered?

Official documents on similar infusion solutions list a feeling of warmth or a burning sensation at the site where the solution is administered as a documented adverse reaction. This reaction is generally categorized as a temporary, local reaction related to the administration process.

Q: Is Rheosorbilact known to cause headaches?

Reports from studies on similar poly-electrolyte solutions indicate that headache is a possible adverse reaction. This type of reaction is thought to be associated with the fluid and electrolyte shifts that the medicine is designed to induce.

Q: What happens if Rheosorbilact is accidentally administered too quickly?

The administration rate is strictly controlled because the risk of severe complications is directly related to the volume and rate of administration. Official safety information indicates that if the solution is administered too quickly, there is a risk of severe fluid and metabolic disturbances, including potentially life-threatening hypervolemia (fluid overload) and pulmonary edema.

Q: Can Rheosorbilact be used for prevention, or only for treatment?

Official documentation lists the general purpose as restoring fluid volume and correcting acute imbalances resulting from significant blood loss or severe dehydration. Research has focused on its use for treatment during critical illness and the immediate acute phase of injury, indicating it is not typically used for prevention.

Q: Why is hydration status important when administering Rheosorbilact?

Regulatory constraints require that patient hydration status be assessed prior to administration to ensure safe use. This is necessary because the solution is formally contraindicated (must not be used) in patients who already have Fluid or Volume Overload, such as hypervolemia.

Q: Are there any clinical trials currently researching new uses for Rheosorbilact?

The current official evidence is based on studies that explored the solution's use in managing acute volume deficit and critical conditions like severe pneumonia or sepsis. Information regarding ongoing studies or the exploration of new uses is typically found by checking official public databases for clinical trials.

Official Storage and Handling Requirements

The storage and handling of Rheosorbilact must strictly adhere to the requirements set forth in the official regulatory labeling. The product has a stated shelf life of 2 years and must be stored at a temperature not exceeding 25 C.

Mandatory Storage Constraints

Constraint Type	Regulatory Requirement
Temperature	Store below 25 C (77 F)
Environmental	Do not freeze
Protection	Keep out of the reach of children

Handling and Stability

To maintain its stability and integrity, Rheosorbilact must not be used as a solvent or carrier for other medicines. Furthermore, the solution is incompatible with, and must not be mixed with, phosphate- or carbonate-containing solutions. Specific instructions for the household disposal of unused or expired product are not typically provided in the official labeling for this clinical product, as waste disposal is governed by institutional protocols.